Navigation Links
FDA Announces Audio Broadcasts on Emerging Drug Safety Information

ROCKVILLE, Md., April 20,2007-The U.S. Food and Drug Administration (FDA) is alerting health care professionals and consumers to the availability of audio broadcasts that provide emerging drug safety information. The broadcasts, commonly known as podcasts, can be transmitted to personal computers and personal audio players.

The service is part of the agency's ongoing effort to broaden and speed its communications concerning the safety of marketed medications when unexpected adverse events are reported to FDA. The broadcasts are an addition to FDA's traditional print- and Web-based public health advisories (PHAs) and anyone can subscribe to them for free at http://www.fda.gov/cder/drug/podcast/default.htm.

"FDA's highest priority is to protect and enhance the health of the American public," said Andrew C. von Eschenbach, M.D., Commissioner of Food and Drugs. "The service contributes to this goal by providing a new venue for busy health care professionals and patients to find drug safety information, so that they don't have to look for it on FDA's Web site or read about it in print. Timely and widely available broadcasts about previously unknown potential drug risks should help ensure that these products are used safely and effectively."

Since the service was launched in February 2007, it has alerted listeners to the potential hazards of skin-numbing products used in hair removal; the voluntary market withdrawals of drugs to treat the symptoms of Parkinson's disease and irritable bowel syndrome, and to serious adverse events associated with agents that reduce the need for blood transfusions in cancer patients.

The American Medical Association (AMA) welcomed the FDA audio broadcast. "This innovative development can help physicians provide the best treatments to their patients and improve patient safety," sa id Edward Langston, M.D., an AMA Board member.

In the broadcasts, FDA asks healthcare providers and patients to report adverse side effects from medical products to MedWatch. MedWatch reports can be made by phone: at 1-800-FDA-1088; fax: 1-800-FDA-0178; or via the Internet at http://www.fda.gov/medwatch/index.html.

Media Inquiries:
S. Mitchell Weitzman, 301-827-6242
Consumer Inquiries:
888-INFO-FDA


'"/>




Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... January 18, 2017 , , Marks E-QURE ... distribution agreement, following similar agreements in Israel ... Wound care is $2 5 billion ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of ... Médica Equipos Médicos S.A.S. (TeckMedica) in Colombia for the ...
(Date:1/19/2017)... 18, 2017   Synthetic Biologics, Inc. ... therapeutics designed to preserve the microbiome to protect ... plans to initiate a Phase 2b/3 adaptive pivotal ... lovastatin lactone designed to reduce methane production by ... gut to treat the underlying cause of irritable ...
(Date:1/18/2017)... PAUL, Minn. , Jan. 18, 2017 /PRNewswire-USNewswire/ ... developer of medical devices using neuroblocking technology to ... today announced the pricing of an underwritten public ... million, prior to deducting underwriting discounts and commissions ... The offering is comprised of Class A Units, ...
Breaking Medicine Technology:
(Date:1/19/2017)... , ... January 19, 2017 , ... ... a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus ... condensed version of the clinic’s leading recovery program. , “We know it’s ...
(Date:1/19/2017)... ... January 19, 2017 , ... Bio-Optronics Inc. is ... modern CTMS workflow designed to seamlessly integrate and streamline the way researchers prepare ... single page, maximizing usability and improving efficiency significantly for users – a first ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... panel system. , The Tranquility privacy panel system was designed to deliver ... Tranquility panels help reduce noise and provide the visual privacy required to maintain ...
(Date:1/19/2017)... ... 19, 2017 , ... Rountree Brady Insurance Agency, a Savannah ... eastern Georgia, is embarking on a charity effort to raise awareness and gather ... every year than anything else, yet risk factors associated with heart disease are ...
(Date:1/19/2017)... ... 2017 , ... Attorney Robert “RC” Pate , founder of The Law ... Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric cancers. ... the effect of the critical funding gap for research into pediatric cancer research. From ...
Breaking Medicine News(10 mins):